Q3 2025 Earnings Call Transcript May 14, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $0.2, ...

Third Quarter 2025 Results Key Financial Results Revenue: US$18.5m (up 2.6% from ...

Boot Barn shares jumped 14.7% to $152.31 in the pre-market trading session. Here are some other stocks moving in pre-market ...

Aytu BioPharma Inc (AYTU) reports significant revenue growth and operational income, despite challenges in gross margins and acquisition valuations.

Discover how Aytu BioPharma achieved 32% revenue growth in Q3 2025, with record numbers in ADHD and pediatric portfolios, signaling strong momentum ahead.

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to ...

Aytu BioPharma (NASDAQ:AYTU) is scheduled to announce Q3 earnings results on Wednesday, May 14th, after market close. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $13.74M ...

DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its ...

Now it’s at $568, and that’s after 6.87% beating today. Regeneron is arguably the most innovative biopharma company I’ve seen in the last two decades. But the stock’s come in significantly ...

The market expects Cue Biopharma, Inc. (CUE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

A biopharmaceutical company in Hinjewadi fell victim to a ransomware attack, with cybercriminals demanding $80,000 for the release of encrypted data. The Pimpri Chinchwad police are investigating ...